SCHEMBL24252519

SCHEMBL24252519

CC(C)Cc1cncc(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 6/20 0.52
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 3/20 0.47
POLB P06746 1/20 0.47
DDO Q99489 1/20 0.47
XDH P47989 1/20 0.40
PTGS1 P23219 3/20 0.40
PTGS2 P35354 3/20 0.40
AKR1C3 P42330 2/20 0.40
CXCR1 P25024 2/20 0.40
CXCR2 P25025 2/20 0.40
ALB P02768 1/20 0.40
ESR1 P03372 1/20 0.40
ALOX5 P09917 1/20 0.40
RARB P10826 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24252516 0.84 CYP11B1 (0.45) POLBALOX5MKNK1MKNK2RAF1
SCHEMBL30281324 0.82 HCAR2 (0.52) HCAR2CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL23990550 0.82 HCAR2 (0.52) HCAR2CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL846393 0.79 CYP2C9 (0.61) HCAR2CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL30281282 0.79 CYP2C9 (0.61) HCAR2CYP2C9CYP2C19KDM4EALDH1A1
SCHEMBL25357564 0.79 HSD17B10 (0.49) HCAR2KDM4EALDH1A1MEN1KMT2A
SCHEMBL31303981 0.79 HSD17B10 (0.49) HCAR2KDM4EALDH1A1MEN1KMT2A
SCHEMBL25357561 0.79 HSD17B10 (0.49) HCAR2KDM4EALDH1A1MEN1KMT2A
SCHEMBL17079743 0.79 CYP2C19 (0.45) CYP2C9CYP2C19KDM4EALDH1A1TSHR
SCHEMBL17079715 0.79 CYP2C19 (0.60) CYP2C9CYP2C19ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303494-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ACADEMY OF MILITARY MEDICAL SCIENCES (CN) 2023-09-28 US disclosed
EP-4198017-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Academy of Military Medical Sciences (CN) 2023-06-21 EP disclosed
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US disclosed
WO-2022033303-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 中国人民解放军军事科学院军事医学研究院 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303494-A1 BENZYLAMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1, PDCD1LG2 HCAR2 1492/4885CYP2C9 1176/4885CYP2C19 1304/4885
US-20230158025-A1 GALACTOKINASE INHIBITORS GALK1, GCK, GCKR HCAR2 3101/4885CYP2C9 3668/4885CYP2C19 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.